Michael Magliochetti, PhD
Mike brings 28 years of successful healthcare operating and acquisition experience to Riverside. Prior to joining Riverside, Mike served as CEO of Claros Diagnostics, a point-of-care in-vitro diagnostic firm, which was honored as one of the Top 50 Most Innovative Companies in the World for 2011 by MIT Technology Review, and acquired by OPKO Health. He previously served as CEO of RMH, a leading orthopedic products company, and as CEO of both HemaMetrics and UroSurge. He has held senior positions with the medical device company Haemonetics and the polymer products company Delta Surprenant, and has completed an assignment with the U.S. Army Research Command. In addition to serving on the Board of Overseers for Boston Museum of Science, Advisory Boards for Boston Children’s Hospital, Lahey Clinic and Medical Development Group-Boston, Mike has also served as an Adjunct Professor of Biomedical Engineering at the University of Iowa and consulted with several medical device and pharmaceutical companies.